Figure 1.
HRs (95% CIs) for pooled canagliflozin 100 and 300 mg vs noncanagliflozin in the incidence of fracture AEs in the 9 individual studies, the pooled non-CANVAS studies, CANVAS, and the overall population. CANA, canagliflozin; MET, metformin; PBO, placebo; SITA, sitagliptin; GLIM, glimepiride; SU, sulfonylurea; PIO, pioglitazone; NA, not assessed.
